Catamenial insulin reactions treated with a long-acting gonadotropin releasing hormone agonist.
Exacerbation of a variety of symptoms during the menstrual cycle is a well-described phenomenon. The exact causes of these changes are poorly understood, and no specific and efficacious therapy has been described. We successfully treated a patient with severe catamenial insulin reactions with a long-acting gonadotropin releasing hormone agonist to suppress menstrual function and added a combination of estrogen and progestin to offset any adverse effect of the resultant hypoestrogenemia for 1 year.
Letterie
G S
GS
Department of Obstetrics and Gynecology, Virginia Mason Medical Center, Seattle, Wash.
Fredlund
P N
PN
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000009:adverse effects*; D016729:Leuprolide / Q000627:therapeutic use*; D008597:Menstrual Cycle / Q000502:physiology*; D008875:Middle Aged; D013997:Time Factors
D007328:Insulin; D016729:Leuprolide